Here the stock is in the tank, there's no research coverage, the company is still losing money, and management wants options on 500, 000 shares for a job well done.
I hope the stockholders tell them where to stick it by voting against. This is one of the lamest, most pathetic managment's I've ever seen. Their pr's are horribly written and just full of blatant hype. Second graders can write better than Edap management. Make that kindergartners.
FDA filing on Ablatherm will probably provide a good selling opportunity in the stock in about a month.